Sutro Biopharma Reports Shareholder Vote Matters
Ticker: STRO · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1382101
| Field | Detail |
|---|---|
| Company | Sutro Biopharma, Inc. (STRO) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Sutro Biopharma filed an 8-K for a shareholder vote on June 6th.
AI Summary
Sutro Biopharma, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders as of June 6, 2024. The filing does not detail the specific matters voted upon but indicates a formal submission to shareholders for their decision.
Why It Matters
This filing indicates that Sutro Biopharma has formally presented matters for a vote by its security holders, which could pertain to significant corporate actions or governance changes.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose specific financial or operational risks.
Key Players & Entities
- SUTRO BIOPHARMA, INC. (company) — Registrant
- June 6, 2024 (date) — Date of earliest event reported
- June 10, 2024 (date) — Date of report
FAQ
What specific matters were submitted for a vote by Sutro Biopharma's security holders?
The provided text of the 8-K filing does not specify the exact matters that were submitted for a vote by Sutro Biopharma's security holders.
On what date were the matters reported in this 8-K submitted for a vote?
The matters reported in this 8-K were submitted for a vote as of June 6, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on June 10, 2024.
What is Sutro Biopharma's principal executive office address?
Sutro Biopharma's principal executive offices are located at 111 Oyster Point Blvd, South San Francisco, California, 94080.
What is Sutro Biopharma's telephone number?
Sutro Biopharma's telephone number is (650) 881-6500.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-06-10 16:30:10
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value STRO The Nasdaq Global Ma
Filing Documents
- stro-20240606.htm (8-K) — 61KB
- 0000950170-24-071335.txt ( ) — 173KB
- stro-20240606.xsd (EX-101.SCH) — 26KB
- stro-20240606_htm.xml (XML) — 4KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On June 6, 2024, the Company held its 2024 Annual Meeting of Stockholders, and the following proposals were adopted: 1. Election of two Class III directors, identified in the table below, each to serve a three-year term, which will expire at the 2027 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes Joseph M. Lobacki 49,578,870 1,393,863 13,906,799 Daniel H. Petree 33,386,033 17,586,700 13,906,799 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: Shares For Shares Against Shares Abstaining 64,598,771 118,896 161,865 3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 50,214,198 171,189 587,346 13,906,799 4. Approval of the amendment of the Company's 2018 Employee Stock Purchase Plan (the " ESPP ") to (i) increase the overall limit on the number of shares that may be issued under the ESPP throughout its ten-year term, and (ii) make certain non-substantive clarifying revisions: Shares For Shares Against Shares Abstaining Broker Non-Votes 50,224,587 618,712 129,434 13,906,799 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sutro Biopharma, Inc. Date: June 10, 2024 By: /s/ Edward Albini Edward Albini Chief Financial Officer